05 5月 2026 by admin in UncategorizedComments Sail Biomedicines Appoints Gene Marcantonio, M.D., Ph.D., as Chief Medical Officer
04 5月 2026 by admin in UncategorizedComments Windward Bio Announces $165M Crossover Financing to Advance Pipeline of Long- Acting Immunology Therapies With Best-in-Disease Potential
04 5月 2026 by admin in UncategorizedComments NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers
28 4月 2026 by admin in UncategorizedComments Avenzo Therapeutics Advances the Combination of CDK4 Selective Inhibitor (AVZO-023) with CDK2 Selective Inhibitor (AVZO-021) in Ongoing Phase 1/2 ORION-1 Study in HR+/HER2- Breast Cancer
22 4月 2026 by admin in UncategorizedComments Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T
14 4月 2026 by admin in UncategorizedComments Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts
07 4月 2026 by admin in UncategorizedComments NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer
27 3月 2026 by admin in UncategorizedComments Zenas BioPharma Anounces Pricing of Concurent Public Oferings of 2.50% Convertible Senior Notes Due 2032 and Comon Stock with Agregate Gros Proceds of $30.0 Milion Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million
23 3月 2026 by admin in UncategorizedComments Tempest Therapeutics Announces Up To $6 Million Private Placement
